RECURRENT LUNG NON-SMALL CELL CARCINOMA

This early-phase study is testing a personalized vaccine made from each patient's unique tumor mutations. The goal is to see if it is safe and can help the immune system fight advanced breast cancer, melanoma, and non-small cell lung cancer. About 25 adults whose cancers have spr…

This study tests whether adding an experimental drug (SX-682) to a standard immunotherapy (pembrolizumab) helps shrink or control advanced non-small cell lung cancer. About 30 adults with stage IIIC or IV lung cancer that hasn't been treated yet will receive both drugs. The goal …

This early-stage trial tests the safety and best dose of combining two drugs—vismodegib and atezolizumab—in adults with advanced non-small cell lung cancer that has returned or spread. Vismodegib blocks certain enzymes that help cancer grow, while atezolizumab helps the immune sy…

This study tests whether adding the immunotherapy drug cemiplimab to the standard two-drug combination (docetaxel and ramucirumab) can help people with advanced or recurrent non-small cell lung cancer live longer. Participants have already tried platinum-based chemotherapy and im…

This study tests a pill called osimertinib in people with advanced non-small cell lung cancer that has a specific genetic change (EGFR exon 20 insertion). The goal is to see if the drug can shrink tumors or slow the cancer's growth. About 46 adults with stage IIIB or IV disease, …

This early-stage trial tests a new treatment for people with a specific type of lung cancer that has spread or come back. The therapy uses the patient's own immune cells, modified to target a protein called folate receptor-alpha (FRa) on cancer cells. Ten participants will receiv…

This early-phase trial tests a new drug (PBF-1129) combined with an existing immunotherapy (nivolumab) in 30 adults with advanced non-small cell lung cancer that has returned or spread. The main goal is to find the safest dose and understand side effects. Researchers also want to…

This study tests whether adding ramucirumab to tepotinib helps control advanced non-small cell lung cancer with a specific MET gene change. About 56 people with stage IV or recurrent cancer will receive either tepotinib alone or with ramucirumab. The goal is to see if the combina…

This early-phase study tests an oral drug called S241656 in adults with advanced cancers that have certain gene changes (KRAS, BRAF, and others). The drug is given alone or with other cancer treatments. The goal is to find safe doses and see if the drug shrinks tumors. About 554 …

This study tests whether combining three targeted drugs (capmatinib, osimertinib, and ramucirumab) works better than two drugs alone for people with advanced non-small cell lung cancer that has specific EGFR and MET gene changes. The drugs block signals that help cancer grow and …

This study looks at how PET/CT scans change during chemoimmunotherapy and radiation in people with stage IV non-small cell lung cancer. Researchers want to see if these scan changes can help predict how well the cancer responds to treatment. About 80 adults who haven't had prior …

This study collects tissue samples from people with various advanced or early-stage cancers to train a new diagnostic platform called Elephas. The goal is to see how accurately it can predict whether a patient will respond to immunotherapy or chemoimmunotherapy. About 324 partici…